Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atorvastatin/ezetimibe - Merck & Co

Drug Profile

Atorvastatin/ezetimibe - Merck & Co

Alternative Names: Ateroclar Combi; Atozet; Atozet Combination Tablets HD; Atozet Combination Tablets LD; Colmibe; Ezetimibe/atorvastatin; Kexrolt; Liptruzet; MK-0653c; Orvatez; SCH-900068; Sersemic; Tioblis; Zardiux; Zoletorv

Latest Information Update: 27 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck/Schering-Plough Pharmaceuticals
  • Developer Merck & Co; Rovi
  • Class Amides; Antihyperlipidaemics; Azetidines; Fatty acids; Fluorobenzenes; Heptanoic acids; Propanols; Pyrroles
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hyperlipidaemia

Most Recent Events

  • 27 Dec 2018 Chemical structure information added
  • 07 Dec 2018 Merck Sharp & Dohme Corp plans a phase III trial for Hypercholesterolaemia (Second line or greater therapy) in China (NCT03768427)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top